Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
Verve Therapeutics was a clinical-stage company developing genetic medicines for cardiovascular disease before its completed acquisition by Eli Lilly and Company. Its public updates centered on in vivo base-editing programs such as VERVE-102, which targets PCSK9 in the liver to reduce LDL-C, along with clinical and regulatory disclosures, operating and financial results, and equity award activity under Nasdaq inducement-grant rules.
Company news also included investor-conference participation, material-agreement and shareholder-voting developments, governance matters, capital-structure disclosure, and risk-factor updates tied to its public-company status and acquisition process.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Verve Therapeutics announces participation in the Guggenheim 2023 Genomic Medicines and Rare Disease Day on April 3, 2023. CEO Sekar Kathiresan will engage in a fireside chat at 10:45 a.m. ET, providing insights into the company's innovative approaches to cardiovascular disease treatment through gene editing.
The event will be available via a live webcast on the company’s website, archived for 30 days. Verve focuses on VERVE-101 and VERVE-201, targeting genes to lower LDL cholesterol, addressing conditions like familial hypercholesterolemia and atherosclerotic cardiovascular disease.
Verve Therapeutics announced promising preclinical data for its gene editing candidate, VERVE-201, aimed at treating homozygous familial hypercholesterolemia (HoFH). The data, presented at the 2023 American College of Cardiology's Annual Scientific Sessions, demonstrated significant, durable editing of the ANGPTL3 gene in non-human primates, achieving up to 96% reduction of ANGPTL3 protein levels and up to 54% reduction in triglycerides. Verve plans to initiate a clinical trial in 2024, targeting patients with HoFH. This single-course gene editing approach may transform cardiovascular disease management, reducing the treatment burden of existing therapies.
Verve Therapeutics reported updates on its clinical pipeline and financial results for Q4 and full-year 2022. The heart-1 clinical trial of VERVE-101 is ongoing in New Zealand and the UK, with initial data expected in H2 2023. The company holds $554.8 million in cash, enough to fund operations into mid-2025. Collaboration revenue reached $1.0 million in Q4 2022, while R&D expenses increased to $37.3 million. The net loss was $41.1 million for the quarter. Positive regulatory advancements include the recent Innovation Passport award for VERVE-101 by the UK MHRA, aiming to accelerate patient access.
Verve Therapeutics has announced that its investigational gene editing medicine, VERVE-101, has received the Innovation Passport designation from the UK’s MHRA for treating heterozygous familial hypercholesterolemia (HeFH). This designation aims to expedite the development and patient access to innovative treatments. VERVE-101 is designed to permanently turn off the PCSK9 gene in the liver, potentially lowering LDL cholesterol levels significantly. The ongoing Heart-1 clinical trial, assessing VERVE-101’s safety and efficacy, is expected to produce initial data in late 2023, which marks a critical step for the company and its mission to transform cardiovascular care.